Recent research have focused on the intersection of GLP-1|GIP|GCGR activator therapies and DA communication. While GCGR activators are widely employed for treating type 2 diabetes mellitus, their unexpected consequences on reinforcement circuits, specifically mediated by DA systems, are attracting significant interest. This article presents a brief